DENMARK — In a historic shift of power on the European corporate stage, Danish pharmaceutical giant Novo Nordisk has knocked luxury conglomerate LVMH off its…
DENMARK — Novo Nordisk, the Danish pharmaceutical giant, has once again seized the spotlight with groundbreaking revelations about its weight loss drug, Wegovy. Following its…
DENMARK — In an effort to meet the escalating demand for its sought-after weight-loss drug, Wegovy, Novo Nordisk has enlisted Thermo Fisher as a contract…
USA — In a bold bid to reshape the landscape of Medicare coverage, Novo Nordisk, the pharmaceutical force behind weight loss therapies Ozempic and Wegovy,…
USA — Viatris Pharmaceuticals is currently awaiting regulatory verdicts on its generic versions of the widely used type 2 diabetes drug Ozempic and the breakthrough…
DENMARK — Novo Nordisk, a pioneering force in diabetes and obesity treatments, is boldly elevating its forecasts following groundbreaking results showcasing the cardiovascular benefits of…
DENMARK —Novo Nordisk has released groundbreaking data from a major trial that showcases Wegovy’s remarkable ability to reduce the risk of “adverse cardiovascular events” by…
DENMARK— Saxenda, a popular obesity medicine from Novo Nordisk, is grappling with limited availability, according to an update posted on the FDA’s drug shortage list.…
NETHERLANDS — In response to reports of patients experiencing thoughts of suicide or self-injury, the European Medicines Agency (EMA) has launched an investigation into weight…
GERMANY — Novo Nordisk, a leading pharmaceutical company, is set to launch its highly popular obesity drug, Wegovy, in Germany this month, marking its third…